Mucopolysaccharidosis I Clinical Trial
Official title:
A Study of Intrathecal Enzyme Replacement Therapy for Spinal Cord Compression in Mucopolysaccharidosis I
The investigators are studying the use of enzyme replacement therapy into the spinal fluid for treatment of spinal cord compression in the Hurler-Scheie and Scheie forms of mucopolysaccharidosis I (MPS I). Funding source -- FDA OOPD
Enzyme replacement therapy (ERT) has been developed for mucopolysaccharidosis I (MPS I), a lysosomal storage disorder. ERT helps many physical ailments due to the disease, but does not treat the central nervous system, due to inability to cross the blood brain barrier. Our purpose is to test delivery of ERT to the spinal fluid via intrathecal injection in patients with MPS I. In this pilot study, we will use recombinant human α-L-iduronidase administered intrathecally once per month for four months to individuals with the Hurler-Scheie and Scheie forms of MPS I and spinal cord compression. If successful, intrathecal delivery could represent a practical, straightforward method of treating central nervous system disease due to lysosomal storage. ;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT01675674 -
Study to Detect Unrecognized Mucopolysaccharidosis in Children Visiting Rheumatology, Hand or Skeletal Dysplasia Clinics
|
N/A | |
| Completed |
NCT00741338 -
Immune Tolerance Study With Aldurazyme® (Laronidase)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
| Completed |
NCT04227600 -
A Study of JR-171 in Patients With Mucopolysaccharidosis I
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04453085 -
An Extension Study of JR-171-101 Study in Patients With MPS I
|
Phase 1/Phase 2 | |
| Completed |
NCT05134571 -
China Post-marketing Surveillance (PMS) Study of Aldurazyme®
|
Phase 4 | |
| Terminated |
NCT00418821 -
A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants
|
Phase 4 | |
| Completed |
NCT03071341 -
Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I
|
Phase 1/Phase 2 | |
| Completed |
NCT03053089 -
Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS I
|
Phase 1/Phase 2 | |
| Completed |
NCT00146757 -
A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old
|
Phase 2 | |
| Active, not recruiting |
NCT04628871 -
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
|
||
| Completed |
NCT02597114 -
Extension Study of AGT-181-102 to Evaluate Long Term Safety and Activity of AGT-181
|
Phase 1 | |
| Terminated |
NCT00748969 -
Clinical Trial of Growth Hormone in MPS I, II, and VI
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05619900 -
Registry of Patients Diagnosed With Lysosomal Storage Diseases
|
||
| Completed |
NCT00146770 -
Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients
|
Phase 3 | |
| Completed |
NCT00176917 -
Stem Cell Transplantation for Hurler
|
Phase 2 | |
| Completed |
NCT00176891 -
Stem Cell Transplant w/Laronidase for Hurler
|
Phase 2 | |
| Active, not recruiting |
NCT03153319 -
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
|
Phase 1/Phase 2 | |
| Completed |
NCT00852358 -
A Study of Intrathecal Enzyme Therapy for Cognitive Decline in MPS I
|
N/A | |
| Enrolling by invitation |
NCT06103487 -
Long Term Follow-Up for RGX-111
|